Holen Sie sich die Stockscreener-App
3.27
5.22%
-0.18
Handel nachbörslich:
3.27
Schlusskurs vom Vortag:
$3.45
Offen:
$3.3
24-Stunden-Volumen:
80,189
Relative Volume:
0.56
Marktkapitalisierung:
$235.75M
Einnahmen:
$5.15M
Nettoeinkommen (Verlust:
$-65.35M
KGV:
-2.4222
EPS:
-1.35
Netto-Cashflow:
$-20.85M
1W Leistung:
-9.92%
1M Leistung:
-6.57%
6M Leistung:
+105.53%
1J Leistung:
+81.67%
1-Tages-Spanne:
$3.1656
$3.4425
1-Wochen-Bereich:
$3.1656
$3.79
52-Wochen-Spanne:
$1.10
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
Vergleichen Sie CLLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
3.27 | 346.12M | 5.15M | -65.35M | -20.85M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-17 | Eingeleitet | Bryan Garnier | Buy |
| 2022-05-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-08 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-03-06 | Herabstufung | Goldman | Neutral → Sell |
| 2019-10-30 | Fortgesetzt | Guggenheim | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Neutral |
| 2019-03-14 | Eingeleitet | William Blair | Outperform |
| 2018-12-19 | Eingeleitet | Goldman | Neutral |
| 2018-07-16 | Eingeleitet | Barclays | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2017-09-05 | Herabstufung | SunTrust | Buy → Hold |
| 2017-09-05 | Bestätigt | Wells Fargo | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-02-28 | Eingeleitet | Wells Fargo | Outperform |
| 2016-04-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-02 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | Eingeleitet | BofA/Merrill | Buy |
| 2015-04-20 | Eingeleitet | Jefferies | Buy |
| 2015-04-20 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Cellectis Adr Aktie (CLLS) Neueste Nachrichten
European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize
Barclays Remains a Buy on Cellectis SA (CLLS) - The Globe and Mail
Barclays raises Cellectis stock price target to $8 on promising cancer therapy - Investing.com Philippines
Jefferies raises Cellectis stock price target to $6 after R&D day - Investing.com
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga
Cellectis reports promising data for lasme-cel in r/r B-ALL - Investing.com
Operating cash flow per share of Cellectis S.A. Sponsored ADR – LSX:A14QZE - TradingView
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
Cellectis’s SWOT analysis: gene therapy firm’s stock poised for growth? - Investing.com
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
European Stocks In The US Close The Week Mostly Steady - Finimize
Biotech And Tech Firms Drive Gains For European ADRs - Finimize
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates - ADVFN Brasil
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal moment - Investing.com
Earnings call transcript: Cellectis Q2 2025 earnings miss drives stock down 13% - Investing.com
Cellectis earnings missed by $0.02, revenue topped estimates - Investing.com India
Cellectis earnings missed by $0.02, revenue topped estimates By Investing.com - Investing.com South Africa
European Stocks Dip As US Holders Turn Cautious - Finimize
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com
European ADRs Inch Higher As Drugmakers Shine - Finimize
Cellectis shares surge 66% following InvestingPro’s April Fair Value alert By Investing.com - Investing.com India
European Stocks Falter On Wall Street As ADR Index Drops - Finimize
European Equities Slip While Biopharma Stocks Shine - Finimize
European Stocks Shine As ADRs Climb Higher - Finimize
European ADRs Dip With Some Stocks Rising Above The Crowd - Finimize
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal year - Investing.com
Finanzdaten der Cellectis Adr-Aktie (CLLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):